Metformin potentiates the effect of arsenic trioxide suppressing intrahepatic cholangiocarcinoma: roles of p38 MAPK, ERK3, and mTORC1

BACKGROUND: Arsenic trioxide (ATO) is commonly used in the treatment of acute promyelocytic leukemia (APL), but does not benefit patients with solid tumors. When combined with other agents or radiation, ATO showed treatment benefits with manageable toxicity. Previously, we reported that metformin am...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Hematol Oncol
Main Authors: Ling, Sunbin, Xie, Haiyang, Yang, Fan, Shan, Qiaonan, Dai, Haojiang, Zhuo, Jianyong, Wei, Xuyong, Song, Penghong, Zhou, Lin, Xu, Xiao, Zheng, Shusen
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2017
Assuntos:
Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5329912/
https://ncbi.nlm.nih.gov/pubmed/28241849
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13045-017-0424-0
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados